Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
11 01 2022
11 01 2022
Historique:
received:
16
02
2021
revised:
04
05
2021
accepted:
20
07
2021
pubmed:
29
7
2021
medline:
22
3
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. 483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)-negative (PRSER-), or ER-positive (PRSER+) breast cancer risk. PRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions. Population-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Sections du résumé
BACKGROUND
Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.
METHODS
483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)-negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.
RESULTS
PRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.
CONCLUSIONS
Population-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Identifiants
pubmed: 34320204
pii: 6329642
doi: 10.1093/jnci/djab147
pmc: PMC8755508
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-122Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
J Clin Oncol. 2004 Feb 15;22(4):735-42
pubmed: 14966099
Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82
pubmed: 24131976
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Ann Oncol. 2016 Sep;27(suppl 5):v103-v110
pubmed: 27664246
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Am J Hum Genet. 2001 Feb;68(2):410-9
pubmed: 11170890
Am J Hum Genet. 1997 Jul;61(1):120-8
pubmed: 9245992
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6
pubmed: 15668471
Am J Hum Genet. 2007 Dec;81(6):1186-200
pubmed: 17999359
Oncologist. 2016 Jun;21(6):716-22
pubmed: 27151655
J Clin Oncol. 2012 Dec 10;30(35):4330-6
pubmed: 23109704
Genet Med. 2020 Oct;22(10):1653-1666
pubmed: 32665703
Br J Cancer. 2011 Oct 11;105(8):1230-4
pubmed: 21952622
J Natl Cancer Inst. 2017 Jul 1;109(7):
pubmed: 28376175
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
J Natl Cancer Inst. 2021 Apr 6;113(4):453-461
pubmed: 32785646
Genet Epidemiol. 2009 Jul;33(5):453-62
pubmed: 19140131
Can J Urol. 2019 Oct;26(5 Suppl 2):17-18
pubmed: 31629419
JAMA. 2015 Apr 7;313(13):1347-61
pubmed: 25849179
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
Breast Cancer Res. 2016 Feb 09;18(1):15
pubmed: 26857456
Cancer Res. 2003 Jan 15;63(2):342-7
pubmed: 12543786
J Clin Oncol. 2017 Jul 10;35(20):2240-2250
pubmed: 28448241
JNCI Cancer Spectr. 2020 Mar 12;4(3):pkaa021
pubmed: 32596635
Eur Urol. 2020 Jan;77(1):24-35
pubmed: 31495749
Nat Commun. 2021 Feb 17;12(1):1078
pubmed: 33597508
JAMA Netw Open. 2020 Jul 1;3(7):e208501
pubmed: 32609350
Clin Breast Cancer. 2021 Feb;21(1):e74-e79
pubmed: 32828665
Breast Cancer Res. 2007;9(2):104
pubmed: 17466083
Curr Oncol Rep. 2016 Jan;18(1):1
pubmed: 26694922
JAMA Oncol. 2020 Aug 1;6(8):1218-1230
pubmed: 32614418
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
Cancer Res. 2010 Dec 1;70(23):9742-54
pubmed: 21118973
Asian J Androl. 2012 May;14(3):409-14
pubmed: 22522501
Cancer Res. 2020 Feb 1;80(3):624-638
pubmed: 31723001
Clin Cancer Res. 2003 Oct 1;9(12):4452-9
pubmed: 14555518
Breast Cancer Res. 2002;4(1):R2
pubmed: 11879560
Br J Cancer. 2012 May 8;106(10):1697-701
pubmed: 22516946
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683